1[1]Sudoh T,Kangawa K,Minamine N,et al.A new natriuretic peptide in porcine brain.Nature,1988,322:78-81.
2[2]Nielsen OW,Kirk V,Bay M,et al.Value of N-terminal probrain natriuretic peptide in the elderly:data from the prospective copenhagen hospital heart failure study (CHHF).Eur Heart Fail,2004,6:275 -279.
3[3]Raymond I,Groenning BA,Hildebrandt PR,et al.The influnce of age,sex and other variables on the plasma level of Nterminal pro brain natriuretic peptide in a large sample of the general population.Heart,2003,89:745-751.
4[4]McCullough PA,Sandberg KR.Sorting out the evidence on natriuretic peptides.Rev Cardio Vasc Med,2003,4(Suppl 4):S13.
7[7]Talwar S,Siebenhofer A,Williams B,et al.Influence of hypertension.Left ventricular hypertrophy,and left ventricular systolic dysfunction on plasma N terminal proBNP.Heart,2000,83:278-282.
8[8]Hobbs FD,Davis RC,Roalfe Ak,et al.Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure:cohort study in representative and high risk community populations.BM,2002,324:1498.
9[9]Bay M,Kirk V,Parner J,et al.NT-proBNP:a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function.Heart,2003,89:150-154.
10[10]Troughton RW,Frampton CM,Yandle TG,et al.Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP)concentrations.Lancent,2000,355:1126-1130.
二级参考文献31
1Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet,1997,350:1349-1353.
2Groenning BA, Nilsson JC, Sondergaard L, et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail, 2001,3:699-708.
3Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation,1997,96:509-516.
4Downie PF, Talwar S, Squire IB, et al. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (Lond),1999,97:255-258.
5Hammerer-Lercher A, Neubauer E, Muller S, et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta, 2001,310:193-197.
6Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet,2000,355:1126-1130.
7Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol, 2002,39:1623-1629.
8Missouris CG, Grouzmann E, Buckley MG, et al. How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. Clin Sci (Lond),1998,94:591-599.
9Berning J,Rokkedal NJ,Launbjerg J,et al.Rapid estimation of left ventricular ejection in acute myocardial infarction by echocardiography wall motion analysis.Cardiology,1992,80:257-266.
10Hunt PJ,Yandle TG,Nicholls MG,et al.The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma.Biochem Biophys Res Commun,1995,214:1175-1183.
